journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Clinical Oncology

journal
https://read.qxmd.com/read/30973374/analysis-of-outcomes-in-patients-with-brca1-2-breast-cancer-mutations-treated-with-accelerated-partial-breast-irradiation-apbi
#1
Faisal Ahmed, Paul J Christos, Prabhsimranjot Singh, Bhupesh Parashar, Alla Gabriella Wernicke
OBJECTIVE: To analyze outcomes and survival for BRCA1/2+ patients treated with accelerated partial breast irradiation (APBI). MATERIALS AND METHODS: Retrospective review was performed on 341 women treated with intracavitary APBI (Mammosite or Contura) postlumpectomy from 2002 to 2013. Patients were treated to 34.0 Gy in 10 BID fractions. Of 341 treated patients, 11 (3.2%) had BRCA1/2 mutations, 5 of whom had an oophorectomy. Ipsilateral breast tumor recurrence (IBTR), contralateral breast tumor recurrence (CBTR), and breast tumor recurrence progression-free survival were analyzed using SPSS-17...
April 9, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30973373/phase-i-study-of-aurora-a-kinase-inhibitor-alisertib-mln8237-in-combination-with-selective-vegfr-inhibitor-pazopanib-for-therapy-of-advanced-solid-tumors
#2
Hiral A Shah, James H Fischer, Neeta K Venepalli, Oana C Danciu, Sonia Christian, Meredith J Russell, Li C Liu, James P Zacny, Arkadiusz Z Dudek
OBJECTIVES: Pazopanib is a multikinase angiogenesis inhibitor. Alisertib is a highly selective inhibitor of mitotic Aurora A kinase. There is preclinical evidence that mitosis-targeting agents exhibit antiangiogenic effects. Thus, the combination of these 2 agents may have a synergistic effect on tumor vasculature. The primary objective of this study is to determine the optimal tolerated dose (OTD) for alisertib and pazopanib. MATERIALS AND METHODS: This phase 1b study evaluated the OTD of alisertib twice a day, on days 1 to 7 with pazopanib, once a day, continuously in a 21-day cycle, both taken orally...
April 9, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30973372/rapid-early-tumor-progression-is-prognostic-in-glioblastoma-patients
#3
Joshua D Palmer, Deepak Bhamidipati, Gaurav Shukla, Dinesh Sharma, Jon Glass, Lyndon Kim, James J Evans, Kevin Judy, Christopher Farrell, David W Andrews, Zi-Wuan Wang, Stephen C Peiper, Maria Werner-Wasik, Wenyin Shi
OBJECTIVES: Determine the prognostic significance of rapid early tumor progression before radiation and chemotherapy for glioblastoma patients. METHODS: A retrospective review of glioblastoma patients was performed. Rapid early progression (REP) was defined as new enhancing tumor or >25% increase in enhancement before radiotherapy. The pre/postoperative magnetic resonance imaging was compared with the preradiation magnetic resonance imaging to determine REP. A blinded review of imaging was performed...
April 9, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30973371/uterine-papillary-serous-carcinoma-arising-in-a-polyp-a-multicenter-retrospective-analysis-on-75-patients
#4
Vincenzo D Mandato, Federica Torricelli, Stefano Palomba, Stefano Uccella, Debora Pirillo, Gino Ciarlini, Pierandrea De Iaco, Emilio Lucia, Giorgio Giorda, Antonino Ditto, Fabio Ghezzi, Francesca Sanseverino, Massimo Franchi, Giuseppe Bifulco, Valentina Mastrofilippo, Martino Abrate, Lorenzo Aguzzoli, Giovanni B La Sala
OBJECTIVES: The objectives of this study were to evaluate whether the international recommendations on the management of uterine papillary serous carcinoma arising in a polyp are uniformly followed in Italian Oncologic Centers and whether the strategy adopted is effective. MATERIALS AND METHODS: Patients with uterine papillary serous carcinoma arising in a polyp and who had undergone a hysterectomy were identified in the 2003-2013 database of 7 Italian Gynecologic Oncology Centers...
April 9, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30973370/conditional-survival-analysis-of-metastatic-colorectal-cancer-patients-living-%C3%A2-24-months-a-single-institutional-study
#5
Nadia D Ali, Kristen Donohue, Shadi Zandieh, Chunxia Chen, Dirk Moore, Elizabeth Poplin, Mihir M Shah, John Nosher, Bin Gui, Salma K Jabbour, Kristen Spencer, Darren R Carpizo
OBJECTIVES: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions. MATERIALS AND METHODS: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155)...
April 9, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30950860/epidemiology-tumor-characteristics-and-survival-in-patients-with-primary-pancreatic-lymphoma-a-large-population-based-study-using-the-seer-database
#6
Dhruvika Mukhija, Sajan Jiv Singh Nagpal, Davendra P S Sohal
INTRODUCTION: Primary pancreatic lymphoma (PPL) is an extranodal manifestation of non-Hodgkin lymphoma originating in the pancreas, which constitutes <1% of all pancreatic neoplasms. Because of the rarity of the disease, most data on PPL are derived from case reports and small case series. To provide better insight into the epidemiology, treatment, and outcomes of these patients, we conducted an analysis of patients with PPL from the Surveillance, Epidemiology and End Results (SEER) database, which is presented in this study...
April 3, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30950859/efficacy-and-safety-of-gefitinib-as-third-line-treatment-in-nsclc-patients-with-activating-egfr-mutations-treated-with-first-line-gefitinib-followed-by-second-line-chemotherapy-a-single-arm-prospective-multicenter-phase-ii-study-re-challenge-ctong1304
#7
Yong Song, Yi-Long Wu, Le-Jie Cao, Jian-Hua Chen, Zhi-Yong Ma, Jiu-Wei Cui, Jie Wang, Hong-Bing Liu, Jing-Yan Ding, Min Hu
OBJECTIVE: There is no standard care for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study aimed to assess the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC patients with EGFR mutation. MATERIALS AND METHODS: It was a multicenter, open-label, single-arm, phase II study. Stage IIIB/IV NSCLC patients with EGFR exon 19del/L858R mutation, who had benefited from first-line gefitinib treatment followed by second-line chemotherapy, received gefitinib 250 mg/d...
April 3, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30932920/atypical-lipomatous-tumors-does-our-inconsistent-terminology-have-patient-repercussions-results-of-a-meta-analysis
#8
Mitchell S Fourman, Carola F van Eck, Kurt R Weiss, Mark A Goodman, Richard L McGough
OBJECTIVES: Misnaming low-grade lipomatous tumors poses a clinical and medicolegal challenge, potentially subjecting patients to expensive and unnecessary surgeries. The terms atypical lipomatous tumor (ALT) and "well-differentiated" liposarcoma (WDL) have been used interchangeably in pathology reports, scholarly works and consensus recommendations, creating vagaries between low-virulence extremity tumors and retroperitoneal disease with metastatic potential. METHODS: A systematic review was performed on all studies that reported on the local recurrence rate and metastasis of ALTs and WDLs in living human subjects...
March 29, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30913092/pathologic-response-to-neoadjuvant-therapy-is-associated-with-improved-long-term-survival-in-high-risk-primary-localized-malignant-peripheral-nerve-sheath-tumors
#9
Elizabeth Shurell-Linehan, Benjamin J DiPardo, Irmina A Elliott, Danielle S Graham, Mark A Eckardt, Sarah M Dry, Scott D Nelson, Arun S Singh, Anusha Kalbasi, Noah Federman, Nicholas M Bernthal, Fritz C Eilber
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) comprise a rare, aggressive subtype of soft tissue sarcoma. While surgery is the mainstay of therapy for this disease, the role of neoadjuvant therapy remains undefined. METHODS: This study reviewed patients 16 years of age and older who underwent surgical treatment for MPNST between 1974 and 2012 at the authors' institution. Univariate and multivariate analyses were performed of clinicopathologic and treatment variables predictive of disease-specific survival (DSS) and disease-free survival...
March 25, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30913091/adjuvant-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-tkis-in-resected-non-small-cell-lung-cancer-nsclc-a-systematic-review-and-meta-analysis
#10
Jacques Raphael, Mark Vincent, Gabriel Boldt, Prakesh S Shah, George Rodrigues, Phillip Blanchette
The role of adjuvant tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) is not well defined. Recent randomized controlled trials showed a disease-free survival (DFS) benefit in patients harboring an epidermal growth factor receptor (EGFR) mutation. Yet, older trials on patients with any EGFR status did not demonstrate the same benefit. We aimed to assess the efficacy and safety of adjuvant TKIs in NSCLC patients. The electronic databases Medline (PubMed) and EMBASE were searched for relevant randomized controlled trials...
March 25, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30913090/bclc-b-subclassification-and-the-hong-kong-liver-cancer-system-in-intermediate-hepatocellular-carcinoma-identifying-candidates-for-curative-therapy
#11
Larisse Longo, Laura B Rodrigues de Freitas, Deivid Santos, Ivana Grivicich, Mário R Álvares-da-Silva
INTRODUCTION: The intermediate stage of the Barcelona Clinic Liver Cancer (BCLC) classification includes a heterogenous population of patients with hepatocellular carcinoma (HCC), and palliative treatment with transarterial chemoembolization is recommended for all of them. In this regard, 2 other classifications could be useful, the subclassification BCLC-B (SUB) and the classification Hong Kong Liver Cancer (HKLC). OBJECTIVE: To determine the indication of curative or palliative treatment between SUB and HKLC in BCLC-B patients...
March 25, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30883390/laparoscopic-assisted-versus-open-d2-gastrectomy-for-advanced-gastric-cancer-in-highly-selective-patients-short-term-surgical-and-chemotherapy-outcomes-of-a-prospective-cohort-study
#12
Xin Huang, Hao Du, Maimaiti Aihemaiti, Teng Liu, Ningyuan Chen, Wenbin Yu, Sanyuan Hu, Shaozhuang Liu
OBJECTIVES: The feasibility and efficacy of laparoscopic-assisted D2 gastrectomy (LAD2G) for advanced gastric cancer (AGC) remain controversial. We conducted a prospective cohort study to provide a comprehensive comparison of LAD2G and open D2 gastrectomy (OD2G) for AGC. MATERIALS AND METHODS: Between April 2016 and December 2017, patients with clinical stage T2-4aN0-3M0 gastric cancer were enrolled and assigned to either LAD2G or OD2G group. The primary endpoint was short-term surgical and chemotherapy outcomes...
March 15, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30883389/radiation-treatment-for-ewing-sarcoma-family-of-tumors-in-adult-patients-a-single-institution-s-experience-over-40-years
#13
Shivam M Kharod, Andre R Spiguel, Joanne P Lagmay, Charles Jones, Christopher G Morris, Charles Parker Gibbs, Robert A Zlotecki
PURPOSE/OBJECTIVES: To report prognostic factors and long-term outcomes in adults with Ewing sarcoma treated with definitive radiotherapy. MATERIALS AND METHODS: We reviewed patients 18 years old and above with nonmetastatic Ewing sarcoma treated with radiotherapy +/- chemotherapy or surgery. Outcomes were stratified by age (30 and above vs. younger than 30 y), soft tissue extension, tumor size (≥8.5 vs. <8.5 cm), tumor location, resection (yes vs. no), and treatment era (1970-1992 vs...
March 15, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30844850/mental-health-disorders-are-more-common-in-colorectal-cancer-survivors-and-associated-with-decreased-overall-survival
#14
Shane Lloyd, David Baraghoshi, Randa Tao, Ignacio Garrido-Laguna, Glynn W Gilcrease, Jonathan Whisenant, John R Weis, Courtney Scaife, Thomas B Pickron, Lyen C Huang, Marcus M Monroe, Sarah Abdelaziz, Alison M Fraser, Ken R Smith, Vikrant Deshmukh, Michael Newman, Kerry G Rowe, John Snyder, Niloy J Samadder, Mia Hashibe
OBJECTIVES: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods. METHODS: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. CRC survivors were matched to individuals from a general population cohort...
March 5, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30844849/ra-223-treatment-for-bone-metastases-in-castrate-resistant-prostate-cancer-practical-management-issues-for-patient-selection
#15
Robert B Den, Daniel George, Christopher Pieczonka, Megan McNamara
Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administration-approved therapies for mCRPC with demonstrated survival benefit. Of these, only radium-223 (Ra-223) specifically targets bone metastases, delays development of skeletal-related events, and improves survival. This review discusses key data from the ALSYMPCA trial, which contributed to the approval of Ra-223...
March 4, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30789414/phase-ib-study-of-induction-chemotherapy-with-xelox-followed-by-radiation-therapy-carboplatin-and-everolimus-in-patients-with-locally-advanced-esophageal-cancer
#16
Nabil F Saba, Seth Force, Charley Staley, Felix Fernandez, Field Willingham, Allan Pickens, Kenneth Cardona, Zhengjia Chen, Laura Goff, Dana Cardin, Eric Lambright, Jon Nesbitt, Alyssa Krasinskas, Kristin Higgins, R Donald Harvey, Taofeek Owonikoko, Suresh S Ramalingam, Dong M Shin, Jonathan J Beitler, Bassel F El-Rayes, Safia Salaria, Wael El-Rifai, Jerome Landry, A B Chakravarthy
PURPOSE: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. We conducted a phase IB trial to determine the recommended phase II dose of everolimus with carboplatin and radiation. MATERIALS AND METHODS: Patients with stage II/III esophageal cancer were enrolled. Following 2 cycles of Capecitabine/Oxaliplatin (XELOX), patients with no disease progression, received 50.4 Gy in 28 fractions and concurrent weekly carboplatin (area under the curve=2), with escalating doses of everolimus...
February 15, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30789413/incidence-of-neonatal-neutropenia-and-leukopenia-after-in-utero-exposure-to-chemotherapy-for-maternal-cancer
#17
Maria La Nasa, John Gaughan, Elyce Cardonick
OBJECTIVE: The main purpose of this article was to report the incidence of neonatal neutropenia or leukopenia after chemotherapy exposure during pregnancy according to the time elapsed between treatment during pregnancy and birth. BACKGROUND: A single study reports 33% of infants exposed to chemotherapy within the last month of pregnancy are born with neutropenia, which can place the newborn at risk for nosocomial infections. On the basis of this report, chemotherapy is typically stopped by 34 weeks of pregnancy to avoid maternal or neonatal myelosuppression at delivery...
February 15, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30789412/phase-ii-trial-of-eribulin-in-patients-with-metastatic-hormone-refractory-prostate-cancer-a-trial-of-the-ecog-acrin-cancer-research-group-e5805
#18
Mark N Stein, Yu-Hui Chen, Michael A Carducci, Gary R Hudes, Pauline M Lerma, Winston W Tan, Robert Dalune, Kendrith M Rowland, Timothy M Kuzel, Robert S DiPaola
BACKGROUND: Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels. METHODS: In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were treated with eribulin 1.4 mg/m as an IV bolus over 5 minutes on days 1 and 8 of a 21-day cycle. This noncomparative study stratified points to either a chemonaive (CN), prior-taxane (Tax) only, or 2 prior cytotoxic (TCx) chemotherapy arm...
February 15, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30789411/effects-of-social-and-contextual-factors-including-marital-status-and-children-on-the-use-of-palliative-chemotherapy-in-metastatic-colorectal-cancer
#19
Shahid Ahmed, Tayyba Baig, Nayyer Iqbal, Duc Le, Haji Chalchal, Adnan Zaidi, Punam Pahwa
BACKGROUND: There is evidence that social and contextual factors such as living alone are associated with outcomes in cancer patients. However, little is known about their influence on the use of palliative chemotherapy in metastatic colorectal cancer (mCRC). In this study, we examined social and contextual factors, including marital status, having children, and distance to a cancer center, for their association with the use of chemotherapy in patients with mCRC. METHODS: A cohort of patients with mCRC diagnosed from 2006 to 2010 in Saskatchewan was evaluated...
February 15, 2019: American Journal of Clinical Oncology
https://read.qxmd.com/read/30768441/concurrent-versus-sequential-chemoradiation-for-low-grade-gliomas-meeting-rtog-9802-criteria
#20
Jeffrey M Ryckman, Adams K Appiah, Elizabeth Lyden, Vivek Verma, Chi Zhang
PURPOSE: Radiation Therapy Oncology Group (RTOG) 9802 has established postoperative radiation therapy (RT) and chemotherapy sequentially as the new standard of care for patients with high-risk low-grade glioma (LGG) meeting trial criteria. Although this trial investigated sequential chemoradiation therapy (sCRT) with RT followed by chemotherapy, it is unknown whether concurrent chemoradiation therapy (cCRT) may offer advantages over sCRT. MATERIALS AND METHODS: The National Cancer Database (NCDB) was queried for newly diagnosed World Health Organization (WHO) grade II glioma...
February 12, 2019: American Journal of Clinical Oncology
journal
journal
28347
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"